Anebulo Pharmaceuticals (ANEB) Long-Term Deferred Tax (2021 - 2023)

Anebulo Pharmaceuticals (ANEB) has reported Long-Term Deferred Tax for 3 consecutive years, with $2.9 million the latest figure, recorded in Q2 2023.

• In Q2 2023, Long-Term Deferred Tax rose 28.59% year-over-year to $2.9 million; the TTM figure through Jun 2023 stood at $2.9 million (up 28.59% YoY), while the FY2023 annual figure was $2.9 million, up 28.59% from the prior year.
• Long-Term Deferred Tax climbed to $2.9 million in Q2 2023 per ANEB's latest filing, from $2.2 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $2.9 million in Q2 2023 and bottomed at $797952.0 in Q2 2021.
• Historically, Long-Term Deferred Tax has averaged $2.0 million across 3 years, with a median of $2.2 million in 2022.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax soared 179.4% — and 2023, when it climbed 28.59%.
• Anebulo Pharmaceuticals' Long-Term Deferred Tax stood at $797952.0 in 2021, then surged by 179.4% to $2.2 million in 2022, then rose by 28.59% to $2.9 million in 2023.
• Business Quant data shows ANEB's Long-Term Deferred Tax at $2.9 million in Q2 2023, $2.2 million in Q2 2022, and $797952.0 in Q2 2021.